97 phenotypes from 3 alleles in 5 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cybbtm1.1Abk/Cybbtm1.1Abk Lyz2tm1(cre)Ifo/? B6.Cg-Lyz2tm1(cre)Ifo Cybbtm1.1Abk	abnormal cued conditioning behavior	J:245699
	abnormal macrophage chemotaxis	J:245699
	decreased body length	J:245699
	decreased body weight	J:245699
	decreased cholesterol level	J:245699
	decreased circulating insulin level	J:245699
	decreased circulating LDL cholesterol level	J:245699
	decreased fasting circulating glucose level	J:245699
	decreased fat cell size	J:245699
	decreased susceptibility to diet-induced obesity	J:245699
	decreased triglyceride level	J:245699
	enlarged spleen	J:245699
	increased brain size	J:245699
	increased circulating HDL cholesterol level	J:245699
	increased epididymal fat pad weight	J:245699
Cybbtm1Din/Y B6.129S-Cybbtm1Din	abnormal blood circulation	J:138704
	abnormal long-term potentiation	J:147954
	abnormal myocardial fiber morphology	J:135786
	abnormal nitric oxide homeostasis	J:101981
	normal cardiovascular system phenotype	J:101981
	decreased body weight	J:135786
	decreased renal plasma flow rate	J:138704
	decreased renal vascular resistance	J:101981, J:138704
	decreased right ventricle systolic pressure	J:135786
	decreased urine sodium level	J:138704
	increased renal glomerular filtration rate	J:101981
	increased renal plasma flow rate	J:101981
	increased urine creatinine level	J:101981
	increased urine nitrite level	J:101981
	increased urine sodium level	J:101981
	oliguria	J:138704
	normal renal/urinary system phenotype	J:101981
Cybbtm1Din/? B6.129S-Cybbtm1Din/J	abnormal atrioventricular cushion morphology	J:306955
	abnormal atrioventricular valve morphology	J:306955
	abnormal cardiac epithelial to mesenchymal transition	J:306955
	abnormal glycosaminoglycan level	J:306955
	abnormal heart development	J:306955
	abnormal heart morphology	J:306955
	abnormal mitral valve morphology	J:306955
	abnormal redox activity	J:306955
	abnormal tricuspid valve morphology	J:306955
	atrial septal defect	J:306955
	atrioventricular septal defect	J:306955
	bicuspid aortic valve	J:306955
	decreased birth weight	J:306955
	decreased cell proliferation	J:306955
	decreased embryo size	J:306955
	embryonic growth retardation	J:306955
	increased apoptosis	J:306955
	postnatal lethality, incomplete penetrance	J:306955
	prenatal lethality, incomplete penetrance	J:306955
	thick mitral valve cusps	J:306955
	ventricular septal defect	J:306955
Cybbtm1Din/Y involves: 129S/SvEv * C57BL/6	abnormal aorta tunica media morphology	J:115614
	abnormal immune system physiology	J:22868
	abnormal macrophage physiology	J:22868
	abnormal neutrophil physiology	J:22868
	cardiac hypertrophy	J:115652
	decreased body weight	J:115614
	decreased systemic arterial blood pressure	J:115614
	decreased systemic arterial systolic blood pressure	J:115652
	increased inflammatory response	J:22868
	increased susceptibility to bacterial infection	J:22868
	increased susceptibility to infection	J:22868
Cybbtm1Din/Cybbtm1Din B6.129S-Cybbtm1Din	abnormal spatial learning	J:111410
	decreased metastatic potential	J:110181
	decreased post-tetanic potentiation	J:111410
	decreased tumor growth/size	J:110181
	decreased vertical activity	J:111410
	granulomatous inflammation	J:146231
	normal immune system phenotype	J:113463
	impaired coordination	J:111410
	increased acute inflammation	J:110181
	reduced long-term potentiation	J:111410
Cybbtm1Din/Cybbtm1Din B6.129S-Cybbtm1Din/J	abnormal circulating chemokine level	J:235399
	abnormal kidney morphology	J:235399
	abnormal macrophage physiology	J:235399
	abnormal renal glomerulus morphology	J:235399
	decreased body weight	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	normal homeostasis/metabolism phenotype	J:194294
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased blood urea nitrogen level	J:235399
	increased circulating creatinine level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
	increased urine protein level	J:235399
Cybbtm1Din/Cybbtm1Din involves: 129S/SvEv * C57BL/6	abnormal aorta tunica media morphology	J:115614
	abnormal intestinal mucosa morphology	J:64232
	abnormal stomach mucosa morphology	J:64232
	decreased body weight	J:115614
	decreased systemic arterial blood pressure	J:115614
	normal digestive/alimentary phenotype	J:64232
	normal immune system phenotype	J:64232
Cybbtm2b(KOMP)Wtsi/Cybbtm2b(KOMP)Wtsi C57BL/6N-Cybbtm2b(KOMP)Wtsi/H	decreased mean corpuscular volume	J:211773
	increased spleen weight	J:211773